1-(2-bromoethyl)indol-3-yl-glyoxylic acid methyl ester | 436160-15-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(2-bromoethyl)indol-3-yl-glyoxylic acid methyl ester
• 英文别名: Methyl 2-[1-(2-bromoethyl)indol-3-yl]-2-oxoacetate
• CAS: 436160-15-5
• 化学式: C₁₃H₁₂BrNO₃
• 分子量: 310.147
• InChiKey: AMOOWQXAOPUEPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  48.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-bromoethyl)indol-3-yl-glyoxylic acid methyl ester 、 2-(1-(3-(dimethylamino)propyl)-1H-indazol-3-yl)acetamide 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-(1-vinyl-1H-indol-3-yl)-pyrrole-2,5-dione
  参考文献：
  名称：

  Novel Indolylindazolylmaleimides as Inhibitors of Protein Kinase C-β:  Synthesis, Biological Activity, and Cardiovascular Safety

  摘要：

  Novel indolylindazolylmaleimides were synthesized and examined for kinase inhibition. We identified low-nanomolar inhibitors of PKC-beta with good to excellent selectivity vs other PKC isozymes and GSK-3 beta. In a cell-based functional assay, 8f and 8i effectively blocked IL-8 release induced by PKC-beta II (IC50 = 20-25 nM). In cardiovascular safety assessment, representative lead compounds bound to the hERG channel with high affinity, potently inhibited ion current in a patch-clamp experiment, and caused a dose-dependent increase of QT(c) in guinea pigs.

  DOI：

  10.1021/jm049478u
• 作为产物：
  描述：

  3-吲哚乙醛酸 在 caesium carbonate 作用下， 以 甲醇 、 正己烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 1-(2-bromoethyl)indol-3-yl-glyoxylic acid methyl ester
  参考文献：
  名称：

  Novel Indolylindazolylmaleimides as Inhibitors of Protein Kinase C-β:  Synthesis, Biological Activity, and Cardiovascular Safety

  摘要：

  Novel indolylindazolylmaleimides were synthesized and examined for kinase inhibition. We identified low-nanomolar inhibitors of PKC-beta with good to excellent selectivity vs other PKC isozymes and GSK-3 beta. In a cell-based functional assay, 8f and 8i effectively blocked IL-8 release induced by PKC-beta II (IC50 = 20-25 nM). In cardiovascular safety assessment, representative lead compounds bound to the hERG channel with high affinity, potently inhibited ion current in a patch-clamp experiment, and caused a dose-dependent increase of QT(c) in guinea pigs.

  DOI：

  10.1021/jm049478u

文献信息

• Indazolyl-substituted pyrroline compounds as kinase inhibitors
  申请人：Zhang Han-Cheng

  公开号：US20080096949A1

  公开（公告）日：2008-04-24

  The present invention is directed to novel indazolyl-substituted pyrroline compounds of Formula (I): useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.

  本发明涉及新型的取代吲唑基吡咯烷化合物，化学式为(I)：用作激酶或双重激酶抑制剂，制备这种化合物的方法以及用于治疗或改善激酶或双重激酶介导的疾病的方法。
• [EN] SUBSTITUTED PYRROLINES AS KINASE INHIBITORS<br/>[FR] PYRROLINES SUBSTITUEES EN TANT QU'INHIBITEURS DE KINASE
  申请人：——

  公开号：WO2003103663A3

  公开（公告）日：2004-07-08
• SUBSTITUTED PYRROLINES AS KINASE INHIBITORS
  申请人：Janssen Pharmaceutica NV

  公开号：EP1513520B1

  公开（公告）日：2008-09-24
• Substituted pyrrolines as kinase inhibitors
  申请人：Zhang Han-Cheng

  公开号：US20070213386A1

  公开（公告）日：2007-09-13

  The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.
• US7232906B2
  申请人：——

  公开号：US7232906B2

  公开（公告）日：2007-06-19